ADTX Company Profile and Key Details
Aditxt, Inc.
ADTX Stock Price Chart
Stock Price Today
Aditxt, Inc. (ADTX) stock declined over -5.82%, trading at $0.11 on NASDAQ, down from the previous close of $0.12. The stock opened at $0.12, fluctuating between $0.11 and $0.12 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Company Information
| Employees | 47 |
| Beta | 1.08 |
| Sales or Revenue | $645.18K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Aditxt, Inc. (NASDAQ: ADTX) stock price is $0.11 in the last trading session. During the trading session, ADTX stock reached the peak price of $0.12 while $0.11 was the lowest point it dropped to. The percentage change in ADTX stock occurred in the recent session was -5.82% while the dollar amount for the price change in ADTX stock was -$0.01.
The NASDAQ listed ADTX is part of Biotechnology industry that operates in the broader Healthcare sector. Aditxt, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Dolly B. Tyan Ph.D.
Senior Vice President of Clinical Devel. Transplantation
Mr. Amro A. Albanna
Co-Founder, Chairman & Chief Executive Officer
Ms. Corinne D. Pankovcin CPA, CPA, M.B.A.
Pres
Mr. Matthew M. Shatzkes
Chief Legal Officer & Gen. Counsel
Ms. Rowena Albanna
Chief Operating Officer
Mr. Thomas J. Farley CPA
Chief Financial Officer
Ms. Maureen Connolly
Chief Content & Engagement Officer
Ms. Corinne D. Pankovcin C.P.A., CPA, M.B.A.
Chief Commercialization Officer
Mr. Ge Chen M.D., M.S.
Senior Vice President of Preclinical Research & Discovery
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.
Co-Founder, Chief Innovation Officer, Sec. & Director
Mr. Matthew M. Shatzkes Esq.
Chief Legal Officer, Gen. Counsel & Corporation Sec.
ADTX's closing price is 6.09% higher than its 52-week low of $0.11 where as its distance from 52-week high of $218.00 is -99.95%.
Number of ADTX employees currently stands at 47.
Official Website of ADTX is: https://www.aditxt.com
ADTX could be contacted at phone 909 488 0844 and can also be accessed through its website. ADTX operates from 737 North Fifth Street, Richmond, VA 23219, United States.
ADTX stock volume for the day was 11.12M shares. The average number of ADTX shares traded daily for last 3 months was 14.67M.
The market value of ADTX currently stands at $1.64M with its latest stock price at $0.11 and 14.23M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com